Back to Search
Start Over
Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
- Source :
- Journal of Clinical Hypertension (Greenwich, Conn.)
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg at 8 weeks, and the percent changes from baseline in low‐density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg at 8 weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow‐up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least‐Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg) groups were −19.3 (2.68) mm Hg and −6.69 (2.76) mm Hg. The difference between the two groups was significant (−12.60 (2.77) mm Hg, 95% CI −18.06 to −7.14, P
- Subjects :
- Male
medicine.medical_specialty
hypertension
Endocrinology, Diabetes and Metabolism
Blood Pressure
amlodipine
030204 cardiovascular system & hematology
telmisartan
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Double-Blind Method
Internal medicine
Internal Medicine
medicine
Humans
Rosuvastatin
030212 general & internal medicine
Amlodipine
Rosuvastatin Calcium
Adverse effect
Antihypertensive Agents
Aged
Dyslipidemias
Original Paper
Combination Therapy
business.industry
Cholesterol
dyslipidemia
Middle Aged
medicine.disease
Discontinuation
Drug Combinations
Blood pressure
chemistry
Cardiology
Drug Therapy, Combination
Female
Telmisartan
Cardiology and Cardiovascular Medicine
business
rosuvastatin
Dyslipidemia
medicine.drug
Subjects
Details
- ISSN :
- 17517176, 15246175, and 03067688
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- The Journal of Clinical Hypertension
- Accession number :
- edsair.doi.dedup.....a9f9dab5c5efdeea3b72febd6d282c04